Pfizer (NYSE:PFE) Trading Up 0.4%

Pfizer Inc. (NYSE:PFE) shares were up 0.4% on Thursday . The stock traded as high as $27.93 and last traded at $27.89. Approximately 7,034,138 shares traded hands during trading, a decline of 84% from the average daily volume of 43,280,914 shares. The stock had previously closed at $27.78.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on PFE shares. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Truist Financial dropped their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Finally, UBS Group cut their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a report on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Trading Down 0.1 %

The company has a market cap of $157.14 billion, a price-to-earnings ratio of 77.25, a P/E/G ratio of 1.24 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a fifty day moving average price of $27.47 and a 200 day moving average price of $29.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the company posted $1.14 EPS. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Institutional Trading of Pfizer

Institutional investors have recently added to or reduced their stakes in the business. Front Street Capital Management Inc. lifted its holdings in Pfizer by 4.3% in the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares in the last quarter. Graves Light Lenhart Wealth Inc. boosted its position in shares of Pfizer by 1.4% during the 2nd quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 281 shares during the last quarter. Infrastructure Capital Advisors LLC raised its stake in Pfizer by 5.2% during the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 284 shares in the last quarter. Castleview Partners LLC grew its position in Pfizer by 2.4% in the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 287 shares in the last quarter. Finally, United Bank lifted its stake in shares of Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.